Among the most critical decisions for optimizing franchise value is pricing, which demands specialized expertise. Strategic Pricing groups in pharmaceutical and biotech companies cut through the institutional complexity to identify critical aspects of the portfolio strategy and support that strategy with sound pricing recommendations. Vice President Rhett Johnson discusses how an effective Strategic Pricing group possesses the regulatory knowledge, functional expertise, strategic vision, and portfolio-wide perspective to lead the organization toward maximum portfolio value. To read this article, click here:
IP Literature Watch: March 2025
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...